Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.13 from other evidence | 0.00 |
| cell type Human Protein Atlas | group enriched outside the brain (monocyte progenitors) | 0.10 |
| chemistry Open Targets | compounds already reach it: verdiperstat | 0.90 |
| trials ClinicalTrials.gov | 4 Parkinson's trials, 1 stopped | 0.80 |
| literature PubMed | 62 Parkinson's papers of 19,500 | 0.46 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 2280
Sealed predictions
- MPO in dopamine neurons, braak-0.01 (p 0.982) → -0.63 (p 0.068)receipt 2287
Swarm cases
receipt 2287: MPO in dopamine neurons, braak
- power
- full sample -0.27 (p 0.277, n 18), 95% CI -0.65 to +0.22. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.29 (p 0.250, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.37 (p 0.132, n 18). could be the mix.
- skeptic
- leave-one-out range -0.43 to -0.17, sign flips 0; without severely affected donors -0.27 (p 0.277, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MPO in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts